NCE and CMC development for peptide drug candidates
Process and analytical development that connects research synthesis to a repeatable drug substance story: route selection, impurity fate, specification rationale and stability—structured phase by phase from preclinical supply through commercial readiness.
5
development phases (typical gate)
ICH
Q3D / Q6A framing (as applicable)
12–24 mo
full dev band (indicative)
COA + method
transferred analytics
Impurity
fate & purge tracking
What NCE / CMC covers for peptides
New chemical entity work for peptides is still small-molecule CMC in regulatory structure: drug substance manufacture, control of impurities, stability and comparability after scale or site change.
Development delivers a documented route (resin, coupling chemistry, cleavage, purification, isolation), validated or qualified analytical methods and a specification proposed for tox and clinical lots—not a single research COA.
Phase-gated development
Manufacturing, analytics, stability and regulatory themes intensify at each phase. Timelines are program-specific.
Preclinical
Manufacturing
Confirm feasible SPPS route; lock salt form; mg–g tox lots
Analytics
Identity, purity, peptide content; preliminary impurity profiling
Stability
Accelerated and stress to guide formulation
Regulatory
CMC outline for non-clinical package
Phase I
Manufacturing
Scale to clinical batch size; define crude vs purified hold points
Analytics
Qualified HPLC/MS; specified impurities list started
Stability
ICH long-term and accelerated protocols initiated
Regulatory
IND module 3 draft; spec justification
Phase II / III
Manufacturing
Campaign planning; optional second site or scale-up
Analytics
Full impurity qualification; chiral or peptide map where needed
Stability
Commitment lots on stability; comparability protocol
Regulatory
Annual updates; DMF or regional equivalent support
PPQ
Manufacturing
Process performance qualification lots at commercial scale
Analytics
GMP release methods; reference standard qualification
Stability
Ongoing stability to support shelf life claim
Regulatory
Pre-approval inspection readiness (sponsor-led)
Commercial
Manufacturing
Routine GMP campaigns; change control
Analytics
Ongoing stability and annual method verification
Stability
Lifecycle management
Regulatory
Post-approval changes and comparability
Typical deliverables by stage
- Development report: route history, critical parameters, impurity fate table
- Master batch record and bill of materials (drug substance)
- Analytical method summaries and validation plan
- Specification proposal with compendial and ICH citations where applicable
- Stability protocol and tabulated results
- Tech transfer package for GMP manufacturing partner
Route decisions early in development
| Topic | Decision | Why it matters |
|---|---|---|
| Length | SPPS vs hybrid ligation | Impurity profile and scalability past ~50 aa |
| Cyclization | On-resin vs in solution | Critical step for specification and purge |
| Purification | RP vs ion exchange vs crystallization | Solvent limits and yield at scale |
| Salt | Acetate vs HCl vs custom | Peptide content and hygroscopicity in drug product |
| API vs formulated DP | Drug substance only vs fill-finish partner | Splits CMC scope between modules |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Impurity categories (peptide DS)
Identification thresholds follow ICH Q3A principles adapted to peptide degradation chemistry.
Deletion / truncation
MS-mapped
n-1, n-2 peptide related substances
Racemization / epimer
Chiral RP or peptide mapping
At labile residues
Oxidation
Relative retention vs main peak
Met, Trp, Tyr
Aspartimide
Specific test for Asp motifs
Especially Asp–Gly
Residuals
Solvents, scavengers, coupling agents
ICH Q3C aligned where applicable
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Frequently asked questions
When the candidate is selected for GLP tox and the specification must survive into the IND. Earlier structured impurity work reduces repeat tox lots.
Related
GMP Peptide API
GMP-manufactured peptide drug substance for clinical trials and commercial demand under a quality system aligned to ICH and regional GMP expectations. Scope is drug substance—synthesis, purification, isolation, release and stability—not discovery-grade custom work.
View detailsCustom Peptide Synthesis
Solid-phase and solution synthesis of linear and modified peptides for discovery, assay development and lead optimization. Scale, purity tier and QC depth are matched to how the material will be used—not every program needs the same finishing step.
View detailsPeptide Modifications
Terminal caps, cyclization, stapling, PTMs, fluorescent and affinity tags, PEG/lipid appendages and unnatural backbones—installed during SPPS or in solution after the chain is built. Each class changes synthesis time, purification and how the product should be specified on the COA.
View detailsGeneric Peptide APIs
Drug substance for approved peptide NCEs—long GLP-1 analogs, somatostatin analogs and GnRH agonists—supplied with analytics suited to generic dossiers. Routes emphasize scalable SPPS or hybrid manufacturing and impurity control against patent-expired reference products.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.